Guangzhou Baiyunshan Pharmaceutical Holdings

Guangzhou Baiyunshan Pharmaceutical Holdings

600332.SS
Guangzhou, China

Guangzhou Baiyunshan Pharmaceutical Holdings is a leading Chinese pharmaceutical company listed on the Shanghai Stock Exchange with a market capitalization of approximately $5.9 billion. The company operates through multiple subsidiaries covering traditional Chinese medicine, modern pharmaceuticals, and consumer healthcare products. With a strong presence in the domestic Chinese market, Baiyunshan has established itself as a major player in China's pharmaceutical industry through both organic growth and strategic acquisitions.

600332.SS · Stock Price

USD 23.223.66 (-13.62%)
Market Cap: $5.5B

Historical price data

AI Company Overview

Guangzhou Baiyunshan Pharmaceutical Holdings is a leading Chinese pharmaceutical company listed on the Shanghai Stock Exchange with a market capitalization of approximately $5.9 billion. The company operates through multiple subsidiaries covering traditional Chinese medicine, modern pharmaceuticals, and consumer healthcare products. With a strong presence in the domestic Chinese market, Baiyunshan has established itself as a major player in China's pharmaceutical industry through both organic growth and strategic acquisitions.

Traditional Chinese MedicineChemical PharmaceuticalsConsumer Healthcare

Technology Platform

Diversified pharmaceutical platform combining traditional Chinese medicine formulations with modern chemical pharmaceutical manufacturing and consumer healthcare products.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
placebo of oseltamivir phosphate + oseltamivir phosphate + B...InfluenzaApproved
Huatuo Zaizao PillsIschemic StrokeApproved
Fufangdanshen Tablets + PlaceboVascular DementiaPhase 2

Opportunities

Well-positioned to capitalize on China's expanding pharmaceutical market, government support for traditional Chinese medicine, and increasing healthcare expenditure from an aging population.

Risk Factors

Faces regulatory uncertainty in China's evolving pharmaceutical sector, increasing competition from domestic and international players, and challenges in standardizing traditional medicine quality control.

Competitive Landscape

Competes with major Chinese pharmaceutical companies like China Resources Pharmaceutical and Sinopharm, differentiated by its combination of traditional Chinese medicine expertise and modern pharmaceutical capabilities.